# Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)

Source: https://onco.cc/terms/staging-systems/  
OnCo record `staging-systems` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Beyond the generic TNM system, gynaecological cancers (FIGO), lymphoma (Ann Arbor, IPI), myeloma (R-ISS), AML (ELN), kidney cancer (IMDC), neuroblastoma (INRG) and CLL (Rai, Binet) each have their own system that combines stage, blood tests, genetics and fitness into risk groups. The name on the report tells you which rulebook sets the treatment intensity.

## Summary

FIGO stages gynaecological cancers (with the 2023 endometrial revision adding molecular class). Ann Arbor/Lugano stages lymphoma and the IPI adds age, LDH, performance status and extranodal sites; R-ISS and R2-ISS combine stage, LDH and cytogenetics in myeloma; ELN 2022 assigns AML to favourable, intermediate or adverse genetic risk that decides transplant; IMDC (Heng) criteria stratify metastatic kidney cancer and select immunotherapy doublets; INRG and COG groups stratify neuroblastoma; Rai and Binet stage CLL. Each maps to a treatment intensity, is the basis of trial eligibility and stratification, and is periodically revised as new markers (ctDNA, MRD, gene expression) prove more predictive.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: FIGO; FIGO stage; AJCC; AJCC 8th edition; UICC; Ann Arbor; Ann Arbor staging; R-ISS; R2-ISS; ISS stage; ELN 2022; ELN risk; IMDC; IMDC risk; Heng criteria; INRG; COG risk group; Rai stage; Binet stage; Masaoka; Enneking; risk group; risk-group; risk stratification; risk-stratified; prognostic index; prognostic score; nomogram

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cancer_staging
- Wikipedia: https://en.wikipedia.org/wiki/Cancer_staging

## Connected records

- terms: [AJCC stage (TNM staging manual)](https://onco.cc/terms/ajcc-stage/), [BCLC staging](https://onco.cc/terms/bclc-staging/), [Cambridge Prognostic Group (CPG 1 to 5)](https://onco.cc/terms/cambridge-prognostic-group/), [CLL-IPI (chronic lymphocytic leukaemia prognostic index)](https://onco.cc/terms/cll-ipi/), [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/), [Performance status (ECOG, Karnofsky)](https://onco.cc/terms/performance-status/), [TNM 9: what changed in lung cancer staging](https://onco.cc/terms/tnm-9-lung-cancer/), [TNM staging](https://onco.cc/terms/tnm-staging/), [TNM staging for prostate cancer, and what changed in the 9th edition](https://onco.cc/terms/tnm-prostate-cancer/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- cancers: [Esthesioneuroblastoma (olfactory neuroblastoma)](https://onco.cc/cancers/esthesioneuroblastoma/), [High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)](https://onco.cc/cancers/high-risk-gtn/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/), [Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)](https://onco.cc/cancers/localised-adrenocortical-carcinoma/), [Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)](https://onco.cc/cancers/low-risk-gtn/), [Lower-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-lower-risk/), [Thymic carcinoma](https://onco.cc/cancers/thymic-carcinoma/), [Thymoma (WHO types A, AB, B1, B2 and B3)](https://onco.cc/cancers/thymoma/)

---
JSON: https://onco.cc/api/v1/entities/staging-systems.json